Related references
Note: Only part of the references are listed.Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
Jhanelle E. Gray et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer
Jeffrey D. Bradley et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2020)
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S. Peters et al.
ANNALS OF ONCOLOGY (2019)
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
Rina Hui et al.
LANCET ONCOLOGY (2019)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Therapeutic management options for stage III non-small cell lung cancer
Stephanie M. Yoon et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer
Suresh Senan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Ross Stewart et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer: The Hoosier Oncology Group and US Oncology
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
